M cell-targeted DNA vaccination.
DNA immunization, although attractive, is poor for inducing mucosal immunity, thus limiting its protective value against most infectious agents. To surmount this shortcoming, we devised a method for mucosal transgene vaccination by using an M cell ligand to direct the DNA vaccine to mucosal inductive tissues and the respiratory epithelium. This ligand, reovirus protein final sigma1, when conjugated to polylysine (PL), can bind the apical surface of M cells from nasal-associated lymphoid tissues. Intranasal immunizations with protein final sigma1-PL-DNA complexes produced antigen-specific serum IgG and prolonged mucosal IgA, as well as enhanced cell-mediated immunity, made evident by elevated pulmonary cytotoxic T lymphocyte responses. Therefore, targeted transgene vaccination represents an approach for enabling DNA vaccination of the mucosa.
Wu
Y
Y
Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717-3610, USA.
Wang
X
X
Csencsits
K L
KL
Haddad
A
A
Walters
N
N
Pascual
D W
DW
D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay; D018014:Gene Transfer Techniques; D051379:Mice; D008807:Mice, Inbred BALB C; D013602:T-Lymphocytes, Cytotoxic / Q000166:cytology / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage* / Q000276:immunology; D017361:Viral Nonstructural Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
D019444:Vaccines, DNA; D017361:Viral Nonstructural Proteins; C071901:sigma 1NS protein, Reovirus